The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.
about
New developments in the management of moderate-to-severe hemophilia BThe safety of pharmacologic options for the treatment of persons with hemophilia.The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality.Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in ItalyGuidelines for assessing appropriateness of pediatric transfusion.NAT screening of blood and plasma donations: evolution of technology and regulatory policy.Hemophilia: treatment options in the twenty-first century.Pathogen inactivation technology: cleansing the blood supply.Transfusion and risk of infection in Canada: UPDATE 2004.Transfusion and risk of infection in Canada: Update 2005.Transfusion and risk of infection in Canada: Update 2006.Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of HemophiliaThe safety of RhIG in the prevention of haemolytic disease of the newborn.Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.Back to the future: a recent history of haemophilia treatment.Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.Clinical use of factor VIII and factor IX concentratesPlasma-derived medicinal products self-sufficiency from national plasma: to what extent?Factor VIII safety: plasma-derived versus recombinant products.Transfusion-related Epstein-Barr virus infection among stem cell transplant recipients: a retrospective cohort study in children.Plasma and plasma derivatives in therapeutic plasmapheresis.Pathogen inactivation and removal methods for plasma-derived clotting factor concentrates.Joint WFH-ISTH session: issues in clinical trial design.Safety of a pasteurized plasma-derived Factor VIII and von Willebrand factor concentrate: analysis of 33 years of pharmacovigilance data.No detection of the retrovirus xenotropic murine leukemia virus-related virus in individuals with hemophilia.A consensus-based tool for ranking the risk of blood-transmissible infections.Errors and Omissions: Donor Compensation Policies and Richard Titmuss.Coagulation Factor IX for Hemophilia B Therapy.Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.Inactivation of parvovirus B19 in coagulation factor concentrates by UVC radiation: assessment by an in vitro infectivity assay using CFU-E derived from peripheral blood CD34+ cells.HBV DNA in plasma pools fractionation.Treatment of hemophilia: recombinant factors only? No.Pharmacokinetic study of minipooled solvent/detergent-filtered cryoprecipitate factor VIII.Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products.Solvent/detergent treatment of platelet concentrates enhances the release of growth factors.
P2860
Q26751323-7913B1F7-27D1-4E18-A272-B5007F86E5A6Q30249200-87A74222-BD94-4705-889E-7F2F189CE4BEQ30249256-FF4E0788-193E-4888-A315-F92D35D78A6EQ33930693-FEFC0AB6-C999-4DED-B459-D5782C5E5FF9Q34416394-4ED5642E-033D-473F-BFA5-F5C2DBF91B96Q34991606-E55CCB18-646D-44A3-92DD-549643A2A88EQ34996023-B5172B15-69EC-429D-9EB0-D44B7C2BB94FQ35181577-1B29BFC7-3425-4C28-A2ED-FC625B40D1D4Q36044573-516AA95A-D00A-450D-BB55-8F082A7E8988Q36170838-F64231BF-DDF4-4A68-9301-9EBDE1D13685Q36171013-0A4651BC-B6B5-47CE-8BE2-D2B5A9BF30B3Q36171185-FB21C8BE-DA87-49FF-8388-E09D1B61A53DQ36196486-E9611184-79FD-4122-ACFC-CCCBB2BE5F69Q36951785-7D0CBEBB-7A5F-4187-8933-FCD84FD4537CQ37139733-2E5E56D9-8324-4F26-874A-CC7DAA3F5A39Q37176481-6361BBB6-43C0-4F21-A8EC-34F847AEC10EQ37370343-DF6ABD59-5962-45FA-A552-EA90B54BFD41Q37370356-24A83984-2428-4BD1-AB54-5B33E58C073CQ37370365-CDA1A4C6-AFBE-41D6-9103-4A9622323DCFQ37882787-6F862C7B-D6E0-417E-91B7-1E5C771E9E65Q37993872-FABC37A2-8CCE-4B4E-AB83-5172235C528FQ38009419-88C006A2-38F9-4871-96E2-7FDBC9551F42Q38151843-53D52EE8-6367-433D-966E-40CFF60C7EB9Q38206863-D0980FF1-E4C5-465C-B4A8-4936C22B68BDQ38687056-82AA2B9D-EAB7-447C-99BB-297BE98B27CFQ40101638-C70578F1-D043-488C-A70A-C2D5D00955D2Q40662421-BCF12A66-5B46-4E78-8F51-FE239E7A1AE9Q41438600-66431F74-2A61-4D36-9570-C84CA02E10B8Q42256024-255A2A9E-8F14-4E3B-889F-E9635DF86E81Q42408107-F7288557-0E2E-48E0-AC60-63A4351B1698Q43584966-1816AF09-C42F-495A-ABE7-88F70A879945Q44571761-113757E2-15FB-4BDE-A47E-4453F2C502D3Q45863913-C3929950-F481-463F-975E-7849346830D4Q45867987-F4F3503C-2CDC-445A-A0C4-5D5CE99BBB59Q45884319-F496B2DB-5E46-4B68-B4A9-E7A6B5948B2AQ45934023-9A729F01-E4CE-4D34-8F9A-5A2A1B5FB748Q46676573-33FC183B-8F5B-430B-A5EB-BCC5F0D68D5C
P2860
The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1.
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The epidemiology of virus tran ...... and C viruses and HIV type 1.
@ast
The epidemiology of virus tran ...... and C viruses and HIV type 1.
@en
type
label
The epidemiology of virus tran ...... and C viruses and HIV type 1.
@ast
The epidemiology of virus tran ...... and C viruses and HIV type 1.
@en
prefLabel
The epidemiology of virus tran ...... and C viruses and HIV type 1.
@ast
The epidemiology of virus tran ...... and C viruses and HIV type 1.
@en
P2860
P1433
P1476
The epidemiology of virus tran ...... and C viruses and HIV type 1.
@en
P2093
P2860
P304
P356
10.1046/J.1537-2995.1999.39111160.X
P577
1999-11-01T00:00:00Z